H.P. Acthar Gel
Sponsors
Stanford University, Fiechtner, Justus J., M.D., P.C., Dent Neuroscience Research Center, The Cleveland Clinic, University of Maryland, Baltimore
Conditions
CNS SarcoidosisChronic MigraineDermatomyositisJuvenile DermatomyositisKidney DiseasesLupus Erythematosus Systemic ExacerbationRheumatoid ArthritisSarcoid Uveitis
Phase 2
Phase 4
Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTH
CompletedNCT01155141
Start: 2009-09-30End: 2014-01-31Updated: 2014-09-01
Open-label Trial of Acthar Gel in Subjects With Moderate to Severe Active Systemic Lupus Erythematosus
CompletedNCT01769937
Start: 2012-10-31End: 2013-04-30Updated: 2013-07-23
Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis
CompletedNCT02245841
Start: 2015-06-15End: 2021-07-14Updated: 2024-06-11
Treatment of CNS Sarcoidosis With H.P. Acthar Gel
CompletedNCT02298491
Start: 2016-05-01End: 2020-11-01Updated: 2026-04-17
Efficacy and Safety of H.P. ACTHAR GEL in Adults With Retinal Vasculitis
NCT03066869
Start: 2017-03-22End: 2020-08-31Target: 40Updated: 2019-09-12
Efficacy, Radiographic and Laboratory Changes in Refractory Rheumatoid Arthritis Patients Treated With H.P. Acthar Gel
NCT03082573
Start: 2017-03-03End: 2019-02-28Target: 30Updated: 2017-03-17